Enanta Pharmaceuticals reported a total revenue of $18.6 million for the fiscal first quarter ended December 31, 2025, an increase from $17.0 million in the same period last year. The company also significantly reduced its net loss to $11.9 million, or $0.42 per diluted common share, compared to a net loss of $22.3 million, or $1.05 per diluted common share, in the prior year.

Enanta Pharmaceuticals posted $15.1 million in revenue for Q4 2025, a marginal increase from the prior year. The company reduced its net loss to $18.7 million, reflecting lower R&D and administrative expenses.

Enanta Pharmaceuticals reported a net loss of $22.6 million, or $1.06 per diluted common share, for the fiscal second quarter ended March 31, 2025. Total revenue was $14.9 million, primarily from royalty revenue. The company ended the quarter with $193.4 million in cash and marketable securities, further strengthened by a $33.8 million tax refund received in April 2025.

Enanta Pharmaceuticals reported a net loss of $22.3 million for the fiscal first quarter ended December 31, 2024, with total revenue of $17.0 million, primarily from MAVYRET®/MAVIRET® royalties. The company is on track with its RSV and immunology programs, with key data readouts and development candidate selections expected in 2025.

Enanta Pharmaceuticals reported a net loss of $28.8 million for the three months ended September 30, 2024, compared to a net loss of $28.1 million for the corresponding period in 2023. Total revenue was $14.6 million, which consisted of royalty revenue, compared to $18.9 million for the three months ended September 30, 2023. The company's cash, cash equivalents and marketable securities totaled $248.2 million at September 30, 2024.

Enanta Pharmaceuticals reported a total revenue of $18.0 million for Q3 2024, primarily from royalty revenue from AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company's cash and marketable securities totaled $272.6 million as of June 30, 2024. Net loss for the quarter was $22.7 million, or $1.07 per diluted common share.

Enanta Pharmaceuticals reported a net loss of $31.2 million for the fiscal second quarter ended March 31, 2024, with total revenue of $17.1 million primarily from royalty revenue. The company is advancing its RSV and immunology programs, anticipating multiple RSV data readouts and selecting a CSU development candidate.

Enanta Pharmaceuticals reported a total revenue of $18.0 million for the three months ended December 31, 2023, consisting of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET®. The net loss for the quarter was $33.4 million, or $1.58 per diluted common share. Cash, cash equivalents and short-term marketable securities totaled $337.2 million at the end of the quarter.

Enanta Pharmaceuticals reported a revenue of $18.9 million for the quarter ended September 30, 2023, compared to $20.3 million for the same period in 2022. The net loss for the quarter was $28.1 million, or $1.33 per diluted common share, compared to a net loss of $26.3 million, or $1.27 per diluted common share, for the corresponding period in 2022. Cash, cash equivalents, and marketable securities totaled $370.0 million at September 30, 2023.

Enanta Pharmaceuticals reported $18.9 million in royalty revenue for the third quarter ended June 30, 2023. The company's net loss was $39.1 million, or $1.86 per diluted share. Cash and marketable securities totaled $392.5 million at the end of the quarter.

Enanta Pharmaceuticals reported a total revenue of $17.8 million for the quarter ended March 31, 2023, primarily from MAVYRET®/MAVIRET® royalties. The company's net loss was $37.7 million, or $1.79 per diluted share. They also strengthened their balance sheet by selling 54.5% of future royalties for $200 million.

Enanta Pharmaceuticals reported revenue of $23.6 million for the quarter ended December 31, 2022, primarily from royalty revenue, and a net loss of $29.0 million, or $1.39 per diluted share. The company's cash, cash equivalents, and marketable securities totaled $241.4 million as of December 31, 2022.

Enanta Pharmaceuticals reported a total revenue of $20.3 million for the quarter, consisting of royalty revenue. The company's net loss was $26.3 million, or $1.27 per diluted common share. Enanta's cash, cash equivalents and marketable securities totaled $278.5 million at September 30, 2022.

Enanta Pharmaceuticals reported a total revenue of $19.5 million for the quarter, primarily from royalty revenue. The net loss for the quarter was $31.7 million, or $1.53 per diluted common share. Cash, cash equivalents, and marketable securities totaled $292.7 million at the end of the quarter.

Enanta Pharmaceuticals reported a revenue of $18.7 million and a net loss of $33.6 million, or $1.63 per diluted common share, for the three months ended March 31, 2022. The company's cash, cash equivalents and short-term and long-term marketable securities totaled $322.5 million at March 31, 2022.

Enanta Pharmaceuticals reported a total revenue of $27.6 million for the three months ended December 31, 2021, consisting entirely of royalty revenue. The company's net loss for the quarter was $30.1 million, or a loss of $1.48 per diluted common share. Enanta expects to begin dosing subjects this month with EDP-235, its SARS-CoV-2 3CL protease inhibitor, and completed enrollment in RSVP, a Phase 2b Study of EDP-938 in adults with community-acquired RSV, with topline data expected in the second quarter of 2022.

Enanta Pharmaceuticals reported a total revenue of $23.6 million for the quarter, consisting of royalty revenue from AbbVie's hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®. Research and development expenses were $48.9 million, and general and administrative expenses totaled $8.4 million. The company recorded a net loss of $24.6 million, or a loss of $1.22 per diluted common share. Enanta's cash, cash equivalents, and marketable securities totaled $352.4 million at September 30, 2021.

Enanta Pharmaceuticals reported a total revenue of $21.6 million for the quarter ended June 30, 2021, primarily from royalty revenue. The net loss was $24.0 million, or $1.19 per diluted common share. Cash, cash equivalents, and marketable securities totaled $372.5 million at the end of the quarter.

Enanta Pharmaceuticals reported a total revenue of $20.1 million for the quarter, primarily from royalty revenue. The company's net loss was $22.0 million, or $1.09 per diluted common share. Cash and marketable securities totaled $400.4 million at the end of the quarter.

Enanta Pharmaceuticals reported a decrease in total revenue due to lower HCV product sales by AbbVie, resulting in a net loss for the quarter, while advancing its pipeline programs in HBV and RSV.

Enanta Pharmaceuticals reported a net loss of $29.3 million for the quarter ended September 30, 2020, compared to a net income of $9.2 million for the same period in 2019. Total revenue for the quarter was $23.6 million, consisting of royalty revenue from AbbVie's hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®. Cash and marketable securities totaled approximately $419 million at September 30, 2020.

Enanta Pharmaceuticals reported a total revenue of $18.7 million, consisting of royalty revenue, for the three months ended June 30, 2020. The net loss for the quarter was $14.3 million, or a loss of $0.71 per diluted common share. The company's cash, cash equivalents, and marketable securities totaled $435.4 million at the end of the quarter.

Enanta Pharmaceuticals reported a total revenue of $27.6 million for the three months ended March 31, 2020, primarily from royalty revenue. The company's net loss for the quarter was $6.0 million, or a loss of $0.30 per diluted common share. Cash and marketable securities totaled $435.4 million at March 31, 2020.

Enanta Pharmaceuticals reported a decrease in revenue compared to the same quarter last year, with $52.6 million in royalty revenue. Net income was $13.4 million, or $0.65 per diluted share. The company's cash and marketable securities totaled $414.7 million.